Home Tags Cancer: Leukemia

Tag: Cancer: Leukemia

The risks for therapy-related myelodysplastic syndrome or acute myeloid leukemia are elevated after chemotherapy use for solid tumors

Myelodysplastic Syndrome/AML Risk Increased After Chemo

Since 2000, risks for therapy-related myelodysplastic syndrome, AML up after chemo for solid cancers

American Society of Hematology, Dec. 1-4

The 60th American Society of Hematology Annual Meeting and Exposition The annual meeting of the American Society of Hematology was held from Dec....
For older patients with untreated chronic lymphocytic leukemia

ASH: Ibrutinib Tops Bendamustine + Rituximab for CLL

Improved progression-free survival with ibrutinib for older adults with untreated CLL
Xospata (gilteritinib) tablets were approved today by the U.S. Food and Drug Administration for treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with an FLT3 mutation

FDA Approves Treatment for AML Patients With Gene Mutation

Expanded approval also granted to mutation assay used to detect FLT3 mutation in AML patients
The U.S. Food and Drug Administration recently announced the approval of Daurismo (glasdegib) tablets for use in combination with a low dose of the chemotherapy cytarabine to treat newly diagnosed acute myeloid leukemia. The treatment is indicated for patients aged 75 years or older who have comorbidities that may prevent the use of intensive chemotherapy.

FDA Approves New Treatment for Acute Myeloid Leukemia

Randomized clinical trial showed significant improvement in overall survival with Daurismo
For patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Duvelisib Promising for Chronic Lymphocytic Leukemia, SLL

Duvelisib extended progression-free survival to 13.3 months versus 9.9 months for ofatumumab
Adolescents and young adults (aged 15 to 39 years) with acute lymphoblastic leukemia (ALL) have increased risk of on-therapy relapse and relapse after completing therapy compared with children with ALL

Risk of Relapse Up for Teens, Young Adults With Leukemia

Increased risk of on-therapy relapse, relapse after completing therapy versus children with ALL
Lumoxiti (moxetumomab pasudotox-tdfk) injection has been approved to treat certain instances of relapsed or refractory hairy cell leukemia

FDA Approves Novel Treatment for Hairy Cell Leukemia

Lumoxiti, a CD22-directed cytotoxin, approved for adults who have had at least two prior therapies
Tibsovo (ivosidenib) tablets have been approved by the U.S. Food and Drug Administration to treat relapsed or refractory acute myeloid leukemia among people with a defective IDH1 gene.

FDA Approves Tibsovo for Acute Myeloid Leukemia

Approved for adults with relapsed or refractory acute myeloid leukemia who have IDH1 mutation
Survivors of lymphoma and chronic lymphocytic leukemia have increased use of health care services versus a normative population

Lymphoma, Leukemia Survivors Have Increased Health Care Use

Survivors who are psychologically distressed use even more services than those who aren't